Table 1.
General characteristics of the study participants
| Entire cohort of patients with PSP | PSP-RS | PSP-non-RS | Healthy controls | p* | p# | |
|---|---|---|---|---|---|---|
| Number of subjects | 148 | 84 | 64 | 20 | − | − |
| Sex (men/women) | 83/65 | 43/41 | 40/24 | 6/14 | 0.03a | 0.17a |
| Age (years) | 65.7 ± 6.8 | 66.3 ± 5.8 | 65.0 ± 7.8 | 56.7 ± 7.3 | < 0.01b | 0.24b |
| Age at onset (years) | 62.0 ± 7.1 | 63.0 ± 6.2 | 60.8 ± 8.0 | N.A | − | 0.07b |
| Disease duration (months) | 38.0 (22.0,60.0) | 38.0 (24.0, 52.0) | 42.0 (18.0, 72.0) | N.A | − | 0.46c |
| PSPrs score | 28.0 (20.0, 37.5) | 32.0 (22.0, 43.0) | 23.5 (17.0, 31.0) | N.A | − | < 0.01c |
| MMSE score | 25 (21, 27) | 24 (19, 27) | 26 (24, 28) | 28 (27, 29) | < 0.01c | < 0.01c |
| Education (years) | 9.0 (8.0, 12.0) | 9.0 (6.0, 12.0) | 11.0 (8.0, 12.3) | 12.0 (9.0,15.8) | 0.01c | 0.12c |
| LEDD (mg) |
400.0 (150.0, 600.0) |
400.0 (150.0, 600.0) |
400.0 (225.0, 650.0) |
N.A | − | 0.65c |
Data are expressed as means ± standard deviations or medians (interquartile ranges), unless otherwise state. Abbreviations: PSP, progressive supranuclear palsy; PSP-RS, progressive supranuclear palsy-Richardson’s syndrome; PSP-non-RS, other PSP subtypes with the exception of progressive supranuclear palsy-Richardson’s syndrome; PSPrs, progressive supranuclear palsy rating scale; MMSE, Mini-Mental State Examination; LEDD, L-dopa equivalent daily dose; N.A., not applicable
* Patients with PSP versus healthy controls; # Patients with PSP-RS versus patients with PSP-non-RS
a Chi-square test; b Student’s t-test; c Mann–Whitney U test